close
Add to watchlist
Allos Therapeutics Inc (ALTH) Healthcare, Biotechnology & Drugs
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumulates preferentially in cancer cells and treats patients with relapsed or refractory peripheral T-cell lymphoma. The company also offers RH1, a small molecule chemotherapeutic agent, which is under Phase I trial to treat patients with advanced solid tumors and non-Hodgkin's lymphoma. In addition, it is evaluating Pralatrexate in various Phases for the treatment of non-Hodgkin's Lymphoma and Hodgkin's disease, cutaneous T-cell lymphoma, non-small cell lung cancer, bladder cancer, and other solid tumor indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.58 |
| Volume | (mio) 2.36 |
| Volume Avg | 489082 |
| 52 Week High | 3.30 |
| 52 Week Low | 1.25 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.24 |
| EPS change Q/Q | -17.65% |
| EPS change Q/Q Yr ago | -30% |
| EPS change Q/Q next Q est | -180% |
| EPS change Y/Y | -20.59% |
| REV change Q/Q | -6.84% |
| REV change Q/Q Yr ago | 47.3% |
| EPS next Q est | -0.05 |
| EPS next Y est | -0.21 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |